CIC
ORIC icon

Cornercap Investment Counsel’s Oric Pharmaceuticals ORIC Stock Holding History

Cornercap Investment Counsel’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,063
Closed -$103K – 518
2024
Q3 		$103K Sell
10,063
-11,675
-54% -$115K 0.03% 489
2024
Q2 		$154K Buy
+21,738
New +$195K 0.03% 554
2023
Q1 		– Sell
-46,485
Closed -$274K – 630
2022
Q4 		$274K Sell
46,485
-22,606
-33% -$76.3K 0.05% 475
2022
Q3 		$221K Buy
69,091
+38,583
+126% +$154K 0.04% 484
2022
Q2 		$137K Buy
+30,508
New +$122K 0.02% 515

Other funds holding ORIC

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cornercap Investment Counsel's ORIC Position: Q4 2024 in Review

Cornercap Investment Counsel sold out of Oric Pharmaceuticals (ORIC) in Q4 2024, closing a stake of 10,063 shares — an estimated $103K sold.

Cornercap Investment Counsel first reported a position in ORIC in Q2 2022 and held it in 5 quarters. The position peaked at $274K in Q4 2022. 129 funds tracked by Wall St. Rank hold ORIC as of Q4 2024.

  • Cornercap Investment Counsel reported no remaining Oric Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 10,063 Oric Pharmaceuticals shares in Q4 2024, an estimated $103K.
  • Cornercap Investment Counsel first reported a position in Oric Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • Cornercap Investment Counsel's Oric Pharmaceuticals position peaked at $274K in Q4 2022.
  • 129 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2024.

Based on Cornercap Investment Counsel's 13F filing for Q4 2024, filed 12 Feb 2025.